Experimental vaccine takes on tough pancreatic cancer

NCT ID NCT07231094

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goal is to check safety, but researchers will also look for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SapDM275 tumor vaccine (targets MICA/B proteins) plus AG chemotherapy (nab-paclitaxel and gemcitabine)
What this could lead to
If it works, this could point toward a new treatment option for metastatic pancreatic cancer, potentially improving tumor shrinkage or delaying progression.
What could go wrong
This is a very early, small trial (13 people) focused on safety, not proof of effectiveness. The vaccine may not shrink tumors or could cause side effects. Many early-stage cancer vaccines fail in later testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Third Xiangya Hospital of Central South University

    Hunan, Changsha, 410000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.